National HealthCare (NHC), Why Is It Back In The Spotlight?
National HealthCare (NHC) has drawn fresh attention after its recent share performance, with the stock around $222.70 and a reported intrinsic discount of about 49%, putting its valuation in focus for healthcare investors.
Over the past year, National HealthCare has combined a sharp year-to-date share price return of 70.77% with a 1-year total shareholder return of 99.63%. This points to strong momentum despite a recent 7-day share price pullback of 4.58% and a softer 1-month share price return of 1.47%.
Scan beyond National HealthCare and compare its sharp run to hand picked 45 high quality undervalued stocks with solid financial profiles and potential valuation gaps.
After a near 100% 1-year total return and a quoted 49% intrinsic discount, National HealthCare now trades in a wide gap between price and valuation models. Is fair value closer to the recent rally or to the implied discount?
Preferred P/E of 24.9x for National HealthCare: Is it justified?
On a simple multiples check, National HealthCare trades on a P/E of 24.9x while the last close was $222.70. That is roughly in line with the broader US Healthcare industry but above the peer group used in the comparison.
The P/E ratio compares the current share price to earnings per share. For a healthcare services company like National HealthCare, this frames what investors are currently paying for each dollar of earnings in a sector where profitability and cash generation are central.
According to the data, National HealthCare is considered good value against the wider US Healthcare industry average P/E of 25x. However, it screens as expensive versus a narrower peer average P/E of 20.1x. That split suggests the current valuation lines up with the sector overall, while implying a premium to closer peers that may reflect its recent earnings growth, profit margin profile, or perceived quality of earnings.
In other words, relative to the industry, the 24.9x P/E does not look stretched. Yet compared with peers, the stock carries a clear premium. If market expectations or earnings trends shift, the P/E could move closer to either the broader industry level or the lower peer average over time.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-earnings of 24.9x (ABOUT RIGHT)
However, the story around National HealthCare can change quickly if earnings soften, or if sector-wide pressure on reimbursement and care costs weighs on margins and sentiment.
Find out about the key risks to this National HealthCare narrative.
Another view on National HealthCare using the SWS DCF model
The SWS DCF model points in a different direction to the 24.9x P/E. With National HealthCare at about $222.70 and an estimated future cash flow value of $437.57, the stock screens as materially undervalued using this approach. Which signal carries more weight for you: the earnings multiple or the cash flow model?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out National HealthCare for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Given the mix of potential upside and clear concerns around National HealthCare, now is a good moment to look through the data yourself and decide how comfortable you feel with the current risk and reward trade off. To help frame that view, take a closer look at the 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond National HealthCare?
If National HealthCare has sharpened your focus on pricing and quality, do not stop here. Broader ideas can help you stress test your convictions and spot fresh angles.
- Target steadier compounding by reviewing companies with strong balance sheets and fundamentals through the list of solid balance sheet and fundamentals (52 results).
- Hunt for potential mispricing by scanning companies that combine quality metrics with valuation support in the 19 high quality undiscovered gems.
- Prioritise capital preservation by checking stocks that carry lower risk scores using the 74 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com